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1. Introduction 
Obesity is a multifactorial disease that affects millions of people worldwide. It is the main 
independent risk factor for developing type 2 diabetes mellitus (T2DM).1,2 Most patients 
with T2DM and glucose intolerance (GI) are overweight, a condition known as diabesity.2,3 
In patients with the most severe form of obesity, i.e. morbid obesity, the likelihood of 
developing diseases associated with obesity is increased.1,4 
We currently know that bariatric surgery provides sustained weight loss and well-
documented remission of T2DM.5,6 Patients who undergo bariatric surgery show long-term 
reduced mortality7 from coronary artery disease, cancer and diabetes; 136 lives are saved 
per 10,000 surgical procedures performed.8 Bariatric surgery is a relatively safe procedure 
that is becoming increasingly well-accepted; in 2007, approximately 170,000 bariatric 
procedures were performed in the USA.6 Currently, bariatric surgery is the most effective 
choice of treatment of morbidly obese patients with diabetes.9 
The surgical procedures that are currently performed to treat morbid obesity are divided 
into two main groups: gastric restrictive procedures and combination procedures; the latter 
combine gastric restriction and malabsorption.10 The roux-en-Y gastric bypass (RYGB) is the 
combination procedure most frequently performed,7,11 whereas sleeve gastrectomy (SG) is 
an emerging restrictive procedure.12 SG can be performed as the first of a two-stage 
operation in patients at high risk of death,13,14 or as a definitive surgical procedure.15 It has 
shown good results with regard to weight loss16 and glycemic control in various 
studies.6,14,16,17 The potential advantages of SG include lower probability of vitamin and 
mineral deficiencies because this procedure has no malabsorptive component; access to the 
entire intestinal tract; no need for a subcutaneous access port or adjustments; absence of 
dumping syndrome and lower probability of intestinal obstruction. In addition, SG can be 
performed in patients who have inflammatory bowel disease or who have undergone bowel 
surgery, and it can be easily converted into RYGB.12,15 Both SG and RYGB can be performed 
with or without the placement of a Silastic® ring.18,19 
The metabolic control achieved with bariatric procedures has been demonstrated and 
reproduced in various medical centers worldwide.6 Metabolic control can be achieved with 
gastric restrictive procedures such as vertical banded gastroplasty,5 adjustable gastric 
banding20 and, more recently, SG.17 However, it has been shown that glucose homeostasis is 
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affected by various intestinal mechanisms observed exclusively in procedures that include a 
malabsorptive element,21 such as RYGB.22-24  
A systematic review of 22,094 cases of morbidly obese patients submitted to bariatric 
surgery has shown that resolution of T2DM was achieved in 76.8% of the cases, 
improvement being achieved in 86% of cases.25 Among the criteria used to diagnose 
metabolic syndrome, fasting glucose levels26 are the first to return to normal in patients 
submitted to Silastic® ring gastric bypass (SRGB), a modification of the traditional RYGB 
which consists in adding a Silastic® ring to the gastric bypass operation. Normoglycemia 
after bariatric procedures, as well as diabesity itself, 27,28 is multifactorial.6,29,30 
Normoglycemia is observed as a result of dietary control,20,21 decreased plasma levels of 
ghrelin,32 weight loss and reduction of body fat6, as well as of the release of gastrointestinal 
hormones that interfere with the function of pancreatic β cells (incretins).23,24,33,34 
To compare the weight loss of morbidly obese patients submitted to either a Silastic® ring 
sleeve gastrectomy (SRSG) or an SRGB, as well as to compare the effects of both procedures 
on glucose homeostasis in morbidly obese patients, our research group developed a study 
that will be better described ahead. 
2. Methods 
2.1 Study protocol 
This was a non-randomized, prospective, controlled clinical study. It was approved by the 
Research Ethics Committee of the University Hospital of the Federal University of Espírito 
Santo, Brazil (protocol no. 049/06) and registered in clinicaltrials.gov, identifier 
NCT00873405. In order to homogenize the sample, we adopted the following inclusion 
criteria: female patients aged 20-60 years, with BMI 40-45 (inclusive), who agreed on giving 
written informed consent. The exclusion criteria adopted were secondary obesity, alcohol or 
drug use, severe psychiatric disorder, binge-eating of sweets and previous stomach or bowel 
surgery. 
2.2 Sample 
Sixty-five female patients were included in the present study. The patients had a mean age 
of 36.03 years, mean BMI of 42.47 and mean waist circumference of 119.62 cm. Mean 
preoperative fasting glucose levels were 103.38 mg/dL (Table 1).  
 
Variables 
Mean, SD, minimum value, maximum 
value 
Age (years) 36.03 ± 9.18 (20-59) 
Body mass index (kg/m2) 42.47 ± 1.64 (40-45) 
Waist circumference (cm) 119.62 ± 8.06 (100-140) 
Fasting glucose levels (mg/dL) 103.38 ± 36.5 (70-320) 
Table 1. Anthropometric data and preoperative fasting glucose levels. 
The diagnoses of diabetes and GI were based on the criteria adopted by the Brazilian Diabetes 
Society.35 T2DM was found in 14 patients (21,5%) and GI, a transitional state to diabetes itself, 
was found in 12 patients (18,5%). Therefore, 40% of the morbidly obese patients analyzed in 
the present study presented with elevated fasting glucose levels (Table 2). 
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Fasting glucose levels n % 
Normal 39 60% 
Glucose intolerance 12 18,5% 
Diabetes 14 21,5% 
Table 2. Prevalence of preoperative type 2 diabetes mellitus and glucose intolerance. 
Most of the diabetic patients used oral hypoglycemic agents (Table 3). 
 
Therapy n % 
Diet 6 9% 
OHG 7 11% 
OHG + Insulin 1 2% 
OHG – oral hypoglycemic agent 
Table 3. Preoperative antidiabetic therapy. 
The 65 patients were divided into two groups; 33 patients (51%) were submitted to SRSG 
(SRSG group), whereas 32 (49%) patients were submitted to SRGB (SRGB group). 
Assessment was performed again 12 to 14 months after the surgery. 
2.3 Surgical procedure 
The surgical procedures were performed between December 08, 2006 and July 27, 2007 at 
Hospital Universitário Cassiano Antonio Moraes from the Universidade Federal do Espírito Santo 
(HUCAM/UFES, Cassiano Antonio Moraes University Hospital, Federal University of 
Espírito Santo). The procedures were performed by the same surgeon using a similar 
anesthetic technique (peridural anesthesia combined with general anesthesia). 
The patients from the SRSG group were submitted to the following procedures: ligation of 
the vessels of the greater curvature of the body and fundus of stomach; resection of the 
fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr 
tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the 
stomach, 5.0 cm below the esophagogastric junction.  
The patients of the SRGB group were submitted to the following procedures: creation of a 
small, proximal gastric pouch and exclusion of a large part of the stomach using a linear 
stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an 
intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® 
ring around the stomach, 5.0 cm below the esophagogastric junction. 
In both groups, the stapled lines were sutured and a methylene blue test was performed to 
verify whether the staple line was secure. The patients were given a liquid diet on the first 
postoperative day and were to be discharged on the third postoperative day. They received 
dietary guidance and instructions regarding physical activities. In addition, patients from 
both groups were prescribed similar vitamin and mineral supplementation. 
2.4 Assessment 
Weight loss, BMI reduction and waist circumference reduction were assessed. The 
percentage of excess BMI loss was calculated as follows: preoperative BMI - current BMI ÷ 
preoperative BMI - 25 × 100.36 Glucose homeostasis was assessed through the measurement 
of fasting glucose levels after the interruption of the pharmacological treatment. 
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2.5 Statistical analysis 
Descriptive analysis was conducted and the results were expressed as means, standard 
deviations, medians, frequency (%), minimum values and maximum values. The Mann-
Whitney test was applied to assess sample variation and homogeneity between groups. 
Fisher’s exact test and chi-square test were employed to compare the results between the 
two groups. The ANOVA was used to assess glucose levels according to time and groups. 
Statistical significance was set at p < 0.05. 
2.6 Results 
In the preoperative period, no significant difference in age, BMI or waist circumference was 
found between patients from the SRSG group and patients from the SRGB group (Table 4).  
 
Variable Group 
Mean, SD, minimum value, 
maximum value* 
Age 
SRSG 36.70 ± 9.4 (20-59) 
SRGB 35.34 ± 9.04 (21-58) 
BMI 
SRSG 42.33 ± 1.5 (40-45) 
SRGB 42.62 ± 1.78 (40.3-44.9) 
Waist circumference (cm) 
SRSG 118.70 ± 5.98 (107-131) 
SRGB 120.58 ± 9.76 (100-140) 
BMI: body mass index. SRSG: Silastic® ring sleeve gastrectomy. SRGB: Silastic® ring gastric bypass. 
*No significant difference was observed between the groups. 
Table 4. Comparison of age, preoperative body mass index and preoperative waist 
circumference between the groups. 
Considering the entire sample, BMI decreased from 42.47 to 27.5 ± 2.67 (p < 0.05). Excess 
BMI loss was 86.18 ± 15% (46.6 – 114.6). In addition, we observed a reduction in waist 
circumference from 119.62 to 90.38 ± 7.9 cm (74 – 108) (p < 0.05). The results obtained with 
both surgical procedures were similar with regard to weight loss, BMI reduction, excess BMI 
loss and waist circumference reduction (Table 5). 
 
Variables SRSG SRGB p 
Weight loss (%) - 34.65 (6.43) - 35.32 (6.20) 0.751 
BMI loss (%) - 35.11 (6.03) - 35.35 (6.22) 0.893 
Excess BMI loss 86.51 (14.20) 85.86 (15.97) 0.954 
waist circumference 
reduction (%) 
- 23.98 (5.42) - 23.95 (7.86) 0.626 
BMI = body mass index. SRSG: Silastic® ring sleeve gastrectomy. SRGB: Silastic® ring gastric bypass. 
Table 5. Comparison of weight loss, BMI reduction, percentage of excess BMI reduction and 
waist circumference reduction between the groups. 
Decreased fasting glucose levels were observed in the postoperative period (p < 0.001), as 
shown in Figure 1. 
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Fig. 1. Preoperative and postoperative fasting glucose levels mg/dl (p < 0.001). 
This decrease was similar in both groups (Table 6).  
 
Group* Period** Fasting glucose levels 
SRSG 
Preoperative 108.5 ± 43.76 (75-320) 
Postoperative 80.79 ± 6.47 (71-98) 
SRGB 
Preoperative 98.25 ± 27.18 (70-218) 
Postoperative 81.04 ± 5.22 (70-91) 
SRSG: Silastic® ring sleeve gastrectomy. SRGB: Silastic® ring gastric bypass. *No significant difference 
was observed between groups. **p < 0.001. 
Table 6. Preoperative and postoperative fasting glucose levels for both groups. 
Both surgical procedures proved effective in promoting the resolution of T2DM and GI in 
the affected patients (p < 0.001), as shown in Table 7. 
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Preoperative T2DM and GI 




37 0 37 
60% 0% 60% 
Present 
25 0 25 
40% 0% 40% 
Total 62 0 62 
T2DM: type 2 diabetes mellitus. GI: glucose intolerance. Groups vs. time, p < 0.001. 
Table 7. Remission of type 2 diabetes mellitus and glucose intolerance in the patients 
affected submitted to surgery. 
All of the patients were able to discontinue the use of oral hypoglycemic agents or insulin, 
or both, during the follow-up period (Figure 2). 
 
Glucose homeostasis box 
Preoperative Postoperative 
n % n % 
Normal 39 60% 62 100% 
Glucose intolerance 12 18% 0 0% 
T2DM - diet 6 9% 0 0% 
Oral hypoglycemic agents 7 11% 0 0% 
Oral hypoglycemic agents + Insulin 1 2% 0 0% 
Total 65 100% 62 100% 
Fig. 2. Progress of glucose homeostasis and treatment of the patients submitted to 
surgery. 
Although it was not the main focus of the present study, it was noteworthy that a fistula 
was developed at the staple line in two (6%) SRSG group patients (p = 0.4936). Both patients 
required reoperation. One of these patients died and the other was submitted to total 
gastrectomy, which led to the resolution of the fistula. 
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The SG procedure has been increasingly used in bariatric surgery.12-17 However, there are 
few prospective clinical studies in the literature that compare that emerging procedure with 
the gold standard.12,17 
In the present study, SG was performed and a Silastic® ring was placed around the stomach. 
We obtained a small, functional stomach, like that obtained with traditional vertical 
gastroplasty, and removed the principal site of ghrelin production, which gave the SRSG the 
characteristics of both bariatric and endocrine surgery.19 The removal of the principal site of 
ghrelin production led to a decrease in ghrelin levels, adding a hormonal element to SRSG, 
which other restrictive procedures such as adjustable gastric banding lack.31 Some authors 
have reported the use of added restriction in SG in order to increase the intensity and duration 
of weight loss19,37,38. In addition, by placing a Silastic® ring around the stomach in all patients 
of our sample, both procedures became identical at the portion located above the ring. 
Gastric bypass is the most used procedure in bariatric surgery and is considered by many 
the gold standard. Some researchers have reported that SG is less risky than RYGB.12-14 
However, in our sample, the most serious complications occurred in the SRSG group, which 
is, albeit not statistically significant, noteworthy. 
Weight loss, BMI reduction, waist circumference reduction and excess BMI loss were 
expressive and similar in both groups. These findings are in accordance with those of some 
studies,12,15,17 but in disagreement with those of other studies13,14 that have regarded SG as 
the first stage of a definitive surgery. The good results of the present study are probably due 
to the judicious selection of the sample, which excluded BMI greater than 45 and patients 
with prior stomach or bowel surgery. In such cases, the results have been admittedly less 
effective. Other factors that might have contributed to the results of the present study 
include the calibration of the remaining stomach using a 32-Fr tube and the placement of a 
Silastic® ring. In other studies in which weight loss was less pronounced, tubes of greater 
caliber were used39 and a Silastic® ring was not placed.13,14 
Resolution of T2DM and decreased incidence of the disease have been well-documented in 
various types of bariatric surgery.5 In two studies of patients submitted to SG, control of 
T2DM was achieved in 80% of the cases.13,14 This remission rate was higher than that 
commonly reported for restrictive procedures such as vertical banded gastroplasty5 and 
adjustable gastric banding;20 it was, however, lower than that obtained with RYGB9,26 and 
biliopancreatic diversion procedures.21 
In the study described above, the rate of clinical remission of GI and T2DM was similar for 
both groups of patients (100%). The reduction in blood glucose levels was also similar for 
both groups, a surprising result that has been reported in another study.17 Because SRSG is 
basically a restrictive procedure that theoretically does not affect incretin expression, it was 
expected that the results obtained with this procedure would be inferior to those obtained 
after procedures with duodenal switch with regard to glucose homeostasis.23,24,29,30 In the 
present study, glucose levels might have decreased as a result of the expressive weight loss 
observed in both groups, which led to increased sensitivity to insulin and decreased 
production of leptin, followed by increased insulin secretion and remission of GI and 
T2DM40. Other hormones produced in the adipose tissue, such as resistin, might also have 
been involved in the glycemic control observed in the present study.41,42 
We should also take into consideration that the patients submitted to surgery in the present 
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The greatest limitation of our prospective, controlled study was the lack of randomization. 
This occurred because the Research Ethics Committee and the authors of this study 
considered that the often irreversible surgical procedures performed in the present study 
could not have been decided on without patient consent. A similar ethical issue was 
reported by the authors of the Swedish Obese Subjects study.5 In order to overcome such 
limitations we selected patients with rather similar characteristics. Both groups comprised 
patients with similar age, BMI, waist circumference and fasting glucose levels in the 
preoperative period. This translated to a superiority of this study over other studies 
conducted previously, in which the groups investigated were not similar,12 the sample was 
not homogeneous15 and the patients included often presented with BMI < 4012,15,17 and/or > 
50.12-17 
The surgical procedures performed in the present study, i.e. SRSG and SRGB, resulted in 
marked weight loss, BMI reduction, waist circumference reduction, excess BMI loss, 
improved glucose homeostasis and remission of GI and T2DM. These results were similar in 
both groups of morbidly obese patients. Further studies should be carried out adopting a 
longer follow-up period, as well as investigating other variables and possible hormonal 
changes, in order to consolidate SRSG. 
With the satisfactory results obtained in the surgical treatment of T2DM through bariatric 
surgery in the last few years, has been evaluated the possibility of expanding the procedure 
indications for patients who are in a lesser degree of overweight. Such conduct has been 
accepted more liberally in patients with BMI between 30 and 35, but there are several 
clinical studies in subjects with BMI between 25 and 30. Recently, the IDF (International 
Diabetes Federation) classified as eligible for metabolic surgery, T2DM patients with BMI 
between 30 and 35.43 
An Australian study, including patients with BMI between 30 and 40, comparing the 
intervention adjustable gastric band vs conventional therapy had remission of T2DM in 73% 
of the subjects against 13% in patients who underwent conventional therapy, with 
improvement in glucose levels, reduction of glycated hemoglobin and decrease of insulin 
plasma levels, demonstrating an improvement in insulinic sensitivity, measured by HOMA 
IR.44 
Preliminary study report using the operation called laparoscopic mini-gastric bypass, 
performed in patients with BMI between 25 and 30, produced the resolution of 
hyperglycemia in 70% of operated patients.45 
Double-blind randomized controlled trial including patients with BMI between 25 and 35 
comparing the operations of gastric bypass vs sleeve gastrectomy showed remission of 
T2DM in both groups. However, the sleeve gastrectomy group remission occurred in 47% of 
patients and gastric bypass in group 93%. Demonstrating the superiority of gastric bypass in 
individuals with less overweight, probably due to the incretin action and the activity 
reduction of dipeptidyl peptidase-4.46 
It should be noted in those patients with BMI between 25 and 35 the importance of a more 
detailed investigation in terms of T2DM pathogenesis, in order to reduce the possibility of 
submitting to surgery patients with complete failure of beta cells or autoimmune disease 
(DMT1ou LADA - Late autoimmune diabetes of adult). The preoperative evaluation of these 
patients should include: concentration of peptide C and tests for markers of pancreatic 
autoimmunity, as anti-glutamic acid dearboxylase (GAD) antibody and anti- Langerhans 
islet antibody. 
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The bariatric-metabolic surgery has unquestionable role in remission (cure?) of T2DM in 
subjects with BMI greater than 35. In this group of patients seems to be no difference in 
remission rates of T2DM between subjects undergoing gastric bypass or sleeve 
gastrectomy. 
In subjects with less overweight, BMI between 30 and 35, nowadays eligible for 
metabolic surgery, gastric bypass seems to be more effective in producing remission of 
T2DM. 
The metabolic surgery in patients with BMI between 25 and 30, still investigational, seems to 
show promising results in remission of T2DM, but further studies should be carried out to 
define its actual role. 
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